Dual RAAS blockade therapies combining a direct renin inhibitor aliskiren with an angiotensin-converting enzyme (ACE) inhibitor or an ARB have been associated with increased risk of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) [5, 6]. The gene discussed is ACE; the disease is acute kidney injury.